Injective is showing signs of a potential trend reversal after months of lower highs and sustained bearish pressure. Analysts say the current price structure near the $3–$4 range could mark an early accumulation phase, while the launch of the Injective Policy Institute adds longer-term optimism around regulatory engagement and ecosystem growth.
